8-K: Tempus AI Announces Q3 2024 Results and Acquisition of Ambry Genetics

Tempus AI reported a 33% year-over-year revenue increase in Q3 2024 and announced the acquisition of Ambry Genetics to expand its genetic testing capabilities.

Summary

• Tempus AI's revenue for the third quarter of 2024 reached $180.9 million, a 33% increase compared to the same period last year.
• Data and services revenue saw a significant boost, growing by 64.4% year-over-year.
• The genomics unit also experienced growth, with a 23.9% annual increase and a rise in average revenue per clinical test.
• The company reported a net loss of $75.8 million, which included $22.2 million in stock compensation expenses and related payroll taxes.
• Adjusted EBITDA improved by $14.4 million year-over-year, reaching a loss of $21.8 million.
• Tempus expects full-year 2024 revenue to be approximately $700 million, representing about 32% annual growth.
• The company has agreed to acquire Ambry Genetics for $375 million in cash and $225 million in shares, with $100 million of the shares subject to a lock-up agreement.
• Ambry Genetics is expected to generate over $300 million in revenue and over $40 million in EBITDA in calendar year 2024.
• The acquisition is partially financed by a $300 million increase in debt from Ares, Tempus' current lender.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a strategic acquisition. However, the ongoing net loss and increased debt are factors that temper the overall sentiment.

Positives

• Revenue increased by 33% year-over-year, indicating strong growth.
• Data and services revenue growth accelerated to 64.4% year-over-year, showing strong performance in this segment.
• Genomics unit growth accelerated to 23.9% annually, with rising average revenue per clinical test.
• Adjusted EBITDA improved by $14.4 million year-over-year, demonstrating progress towards profitability.
• The acquisition of Ambry Genetics is expected to expand testing capabilities and enter new disease categories.
• Ambry Genetics is currently growing at over 25% a year and generates meaningful EBITDA and cash flow.
• The company has secured a multi-year collaboration with BioNTech and a 3-year extension with Merck EMD.
• The company initiated a collaboration with OneOncology to bring more biomarker-driven trials to patients.
• The company initiated the beta launch of its patient-facing app, Olivia.

Negatives

• The company reported a net loss of $75.8 million for the quarter.
• The net loss included $22.2 million in stock compensation expenses and related employer payroll taxes.
• Non-GAAP Genomics gross margin decreased to 49.3% from 51.9% in the same quarter last year, largely related to one-time cash payments in 2023.
• The company is taking on $300 million in additional debt to finance the Ambry Genetics acquisition.

Risks

• The company is still operating at a loss, with a net loss of $75.8 million for the quarter.
• The company is taking on a significant amount of debt to finance the Ambry Genetics acquisition.
• The company's ability to successfully integrate Ambry Genetics and realize the expected benefits is not guaranteed.
• The company faces risks related to competition, new market entrants, and compliance with evolving regulations, including those in the artificial intelligence space.
• The company's future financial performance is subject to various risks and uncertainties, including the ability to attract and retain customers and partners.

Future Outlook

Tempus expects full-year 2024 revenue of approximately $700 million, representing approximately 32% year-over-year growth and approximately ($105 million) in adjusted EBITDA, an improvement of approximately $50 million over 2023.

Management Comments

• Eric Lefkofsky, Founder and CEO of Tempus, stated that the overall business performed well in the quarter, with accelerating volume growth in the genomics business and accelerating revenue growth in the data and services business.
• Eric Lefkofsky also expressed excitement about the pending acquisition of Ambry Genetics, noting that it broadens the testing portfolio, expands disease coverage, and enhances the types of products offered to biotech and pharmaceutical partners.
• Eric Lefkofsky noted that Ambry's revenues are currently growing at north of 25% a year and it generates meaningful EBITDA and cash flow.

Industry Context

This announcement reflects a trend in the healthcare industry towards precision medicine and the use of AI to improve patient care. The acquisition of Ambry Genetics positions Tempus to expand its offerings in genetic testing, a growing area of healthcare. The collaboration with BioNTech and Merck EMD also highlights the increasing importance of data and partnerships in the pharmaceutical and biotech sectors.

Comparison to Industry Standards

• Tempus's 33% year-over-year revenue growth is strong compared to many established healthcare companies, but it is important to compare it to other high-growth companies in the precision medicine and AI space.
• The adjusted EBITDA loss of $21.8 million, while an improvement, indicates that the company is still in a growth phase and not yet profitable, which is common for companies in this sector.
• The acquisition of Ambry Genetics is a significant move, similar to other companies in the space that are consolidating to expand their offerings and market share. Companies like Exact Sciences and Invitae have also made acquisitions to expand their testing portfolios.
• The expected revenue of $700 million for 2024 is a key metric to watch, and it will be important to see how this compares to other companies in the space, such as Guardant Health and Foundation Medicine.
• The data and services revenue growth of 64.4% is particularly impressive and suggests that Tempus is successfully monetizing its data assets, which is a key differentiator in the industry.

Stakeholder Impact

• Shareholders will be impacted by the acquisition of Ambry Genetics and the associated debt financing.
• Employees may experience changes due to the integration of Ambry Genetics.
• Customers will benefit from the expanded testing capabilities and product offerings.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors will be impacted by the increase in debt.

Next Steps

• The company will complete the acquisition of Ambry Genetics.
• The company will continue to integrate Ambry Genetics into its operations.
• The company will continue to execute on its strategic collaborations with BioNTech, Merck EMD, and OneOncology.
• The company will continue to develop and refine its patient-facing app, Olivia.
• The company will host a conference call and webcast to discuss the results.

Key Dates

Keywords

Tempus AI, Ambry Genetics, Acquisition, Genomics, Precision Medicine, Genetic Testing, AI, EBITDA, Revenue, Financial Results